1. CDC, Animals and Rabies. Available from: https://www.cdc.gov/rabies/animals/index.html. (2024).
2. WHO, Human and dog rabies prevention and control: report of the WHO. Bill and Melinda Gates Foundation Consultation, Annecy, France, 7-9 October 2009. , (2010).
3. Anonymus, The Rabies Road Map. https://www.unitedagainstrabies.org/the-rabies-roadmap/, (2023).
4. Walker, P. J., Siddell, S. G., Lefkowitz, E. J. et al., Recent changes to virus taxonomy ratified by the International Committee on Taxonomy of Viruses. Arch Virol 167, 2420-2440 (2022).
5. Fooks, A. R., Cliquet, F., Finke, S. et al., Rabies. Nat Rev Dis Primers 3, 17091 (2017).
6. Wiktor, T. J., Koprowski, H., Antigenic variants of rabies virus. . J Exp Med 52, 99–112. (1980).
7. Blasdell, K. R., Guzman, H., Widen, S. G. et al., Ledantevirus: A proposed new genus in the Rhabdoviridae has a strong ecological association with bats. . Am J Trop Med Hyg 92, 405–410
(2015).
8. Shipley, R., Wright, E., Selden, D. et al., Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU. Trop Med Infect Dis 4, (2019).
9. Walker, P. J., Firth, C., Widen, S. G. et al., Evolution of genome size and complexity in the rhabdoviridae. . PLoS Pathog. 13, 1004664 (2015).
10. Kuzmin, I. V., Wu, X., Tordo, N. et al., Complete genomes of Aravan, Khujand, Irkut and West Caucasian bat viruses, with special attention to the polymerase gene and non-coding regions. .
Virus Res 136, 81-90 (2008).
11. Ogino, T., Green, T. J., Transcriptional Control and mRNA Capping by the GDP Polyribonucleotidyltransferase Domain of the Rabies Virus Large Protein. Viruses 11, (2019).
12. Coslett, G. D., Holloway, B. P., Obijeski, J. F., The structural proteins of Rabies virus and evidence of their synthesis from separate monocistronic RNA species. J Gen Virol 49, 161-180 (1980).
13. Sokol, F., Stancek, D., Koprowski, H., Structural proteins of Rabies virus. Journal of Virology 7, 241-249 (1971).
14. Finke, S., Mueller-Waldeck, R., Conzelmann, K. K., Rabies virus matrix protein regulates the balance of virus transcription and replication. J Gen Virol 84, 1613-1621 (2003).
15. Gillet, J. P., Derer, P., Tsiang, H., Axonal Transport of Rabies Virus in the Central Nervous System of the Rat. Journal of Neuropathology and Experimental Neurology 45, 619-634 (1986).
16. Schnell, M. J., McGettigan, J. P., Wirblich, C. et al., The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 8, 51-61 (2010).
17. Bourhy, H., Rollin, P. E., Vincent, J. et al., Comparative Field Evaluation of the Fluorescent Antibody Test, Virus Isolation from Tissue Culture, and Enzyme Immunodiagnosis for Rapid
Laboratory Diagnosis of Rabies. Journal of Clinical Microbiology 27, 519-523 (1989).
18. Warrell, M. J., Warrell, D. A., Rabies and other lyssavirus diseases. . Lancet 363, 959-969 (2004).
19. Laothamatas, J. B., Ampawong, S., Tepsumethanon, V. et al., Furious and paralytic rabies of canine origin: neuroimaging with virological and cytokine studies. . Journal of Neurovirology 14,
119-129 (2008).
20. Tirawatnpong, S., Hemachudha, T., Manutsathit, S. et al., Regional distribution of rabies viral antigen in central nervous system of human encephalitic and paralytic rabies. . Journal of Neuro-
logical Sciences 92, 91-99 (1989).
21. Hemachudha, T., Wacharapluesadee, S., Mitrabhakdi, E. et al., Pathophysiology of human paralytic rabies. . Journal of Neurovirology 11, 93–100 (2005).
22. Fooks, A. R., Banyard, A. C., Horton, D. L. et al., Current status of rabies and prospects for elimination. Lancet 384, 1389–1399 (2014).
23. Hemachudha, T., Ugolini, G., Wacharapluesadee, S. et al., Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol. 12, 498–513 (2013).
24. Müller, T., Freuling, C. M., Wysocki, P. et al., Terrestrial rabies control in the European Union: historical achievements and challenges ahead. . Vet J. 203, 10-17 (2015).
25. Banyard, A. C., Tordo, N., Rabies pathogenesis and immunology. Rev Sci Tech 37, 323-330 (2018).
26. Riccardi, N., Giacomelli, A., Antonello, R. M. et al., Rabies in Europe: An epidemiological and clinical update. Eur J Intern Med. 88, 15-20 (2021).
27. WHO, Rabies vaccines: WHO position paper, April 2018 – Recommendations. Vaccine 36, 5500-5503 (2018).
28. Gavi, Gavi launches new programme to increase access to lifesaving rabies vaccines. Available from: https://www.gavi.org/news/media-room/gavi-launches-new-programme-increase-access-li-
fesaving-rabies- vaccines (2024).
29. ACIP, Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies. MMWR Recomm Rep 59, 1-9 (2010).
30. Huang, Y., Liu, X., Song, S. et al., mRNA vaccines encoding the RABV glycoprotein protect mice against lethal RABV challenge. Virology 580, 82-92 (2023).
31. Liu, Y., Li, X., Ma, J. et al., Heterologous prime-boost immunization with mRNA and protein vaccines against RABV. Vaccine 41, 3891-3899 (2023).
32. Slate, D., Algeo, T. P., Nelson, K. M. et al., Oral Rabies Vaccination in North America: Opportunities, Complexities, and Challenges. PLoS Negl Trop Dis 3, e549 (2009).
33. Maki, J., Guiot, A. L., Aubert, M. et al., Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG): a global review. Vet Res 48, 57 (2017).
34. Vos, A., Müller, T., Cox, J. et al., Susceptibility of ferrets (Mustela putorius furo) to experimentally induced rabies with European Bat Lyssaviruses (EBLV). J Vet Med B Infect Dis Vet Public
Health 51, 55-60 (2004).
35. Fehlner-Gardiner, C., Rudd, R., Donovan, D. et al., Comparing ONRAB® and RABORAL V-RG® oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada,
and Maine, USA. J Wildl Dis 48, 157-167 (2012).
36. Ma, X., Monroe, B. P., Cleaton, J. M. et al., Rabies surveillance in the United States during 2018. J Am Vet Med Assoc 256, 195-208 (2020).
37. Rosatte, R., Donovan, D., Allan, M. et al., The control of raccoon rabies in Ontario Canada: proactive and reactive tactics, 1994-2007. J Wildl Dis 45, 772-784 (2009).
38. Khawplod, P., Wilde, H., Sirikwin, S. et al., Revision of the Thai Red Cross intradermal rabies post- exposure regimen by eliminating the 90-day booster injection. Vaccine 24, 3084-3086 (2006).
39. Nagarajan, T., Mohanasubramanian, B., Seshagiri, E. V. et al., Molecular epidemiology of rabies virus isolates in India. J Clin Microbiol 47, 3645-3651 (2009).
40. Bakker, A. B., Python, C., Kissling, C. J. et al., First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26,
5922-5927 (2008).
41. Sloan, S. E., Hanlon, C., Weldon, W. et al., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25, 2800-
2810 (2007).
42. De Benedictis, P., Minola, A., Tegshduuren, E. et al., Human rabies encephalitis prevention and treatment: progress and future perspectives. Expert Rev Anti Infect Ther 14, 1-14 (2016).
43. Gogtay, N. J., Thatte, U. M., Kshirsagar, N. A. et al., Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine
30, 7315-7320 (2012).
44. Both, L., Banyard, A. C., van Dolleweerd, C. et al., Passive immunity in the prevention of rabies. Lancet Infect Dis 12, 397-407 (2012).
45. WHO, Rabies vaccines: WHO position paper – April 2018. Wkly Epidemiol Rec 93, 201-220 (2018)